Shennon Biotechnologies

United States - San Francisco, California

• 14/03/2023
• Seed
• $13,000,000

ShennonBio has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level at unprecedented throughput and accuracy, which resolves a key bottleneck in immunotherapy. We utilize the platform to functionally profile immune cells and their cognate antigens and apply this knowledge to develop more effective therapies against solid tumors and autoimmune diseases. Based in San Francisco next to UCSF Mission Bay, we are funded by DCVC, Foundation Capital and AV8.

www.shennonbio.com

Related People

Li SunFounder

United States - San Francisco, California

Scientist, Entrepreneur, Former VC. Passionate about inventing technologies that transform human life and turning those technologies into products that have a lasting positive impact to the world. Currently leading ShennonBio to develop more effective immunotherapies. Coming from an engineering background, I believe in applying 1st principles in problem solving, which often leads to the most simple solutions.

I have a B.Eng in EE and Business from NTU in Singapore, M.Eng in Materials Science from MIT and PhD in Applied Physics from Harvard focusing on single cell analysis.

As a former VC, I focused on deep tech startups that employ technology innovations to solve critical global scale problems, and invested in many areas covering AI, advanced chips, space tech, robotics, clean tech and drug discovery.

LinkedIn https://www.linkedin.com/in/li-sun-phd-6040271b/